Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Sponsors › Genomics: Clinical Implementation › UK's NICE Finalizing Updated Breast Cancer Test Guidance Following Stakeholder Comments

UK's NICE Finalizing Updated Breast Cancer Test Guidance Following Stakeholder Comments

Feb 07, 2018
|
Molika Ashford
Premium

NEW YORK (GenomeWeb) – After releasing a draft document last month updating its recommendations regarding the use of molecular tests to guide chemotherapy decisions for breast cancer patients, the UK's National Institute for Health and Care Excellence (NICE) is now evaluating comments from stakeholders ahead of an expected finalization in May.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Oct
08
Featured Webinar

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct
14
Featured Webinar

Application of ctDNA Analysis to Detect MRD and Predict Recurrence in Colorectal Cancer

Sponsored by
Inivata

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.

Oct
15
Featured Webinar

A Comparison of cfDNA Approaches to Guide Targeted Therapy in NSCLC

In non-small cell lung cancer (NSCLC), early detection of emerging resistance mutations such as EGFR T790M is important in order to determine the appropriate targeted therapeutic strategy.

Oct
29
Featured Webinar

How to Train Your DRAGEN for Pathology Informatics

Illumina’s BaseSpace Sequence Hub (BSSH) supports primary and secondary analysis of massively parallel sequencing data and can be applied to gene panel data that is generated as part of a clinical cancer assay performed in a pathology lab.

What's Popular?

In Molecular Diagnostics

  1. Metastatic Cancer Treatment Markers Identified in Clinical WGS Study

  2. Roche's Ipatasertib, Anti-Androgen Therapy Improves Outcomes in Prostate Cancer With PTEN Loss

    Premium

  3. Natera Cancer Liquid Biopsy Test Coverage to Expand Under New Draft LCD

  4. Biovica Files FDA 510(k) Submission for Breast Cancer Treatment Response Assay

  5. Illumina to Acquire Grail for $8B in Cash and Stock

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.